Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + lurbinectedin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of three drugs—bevacizumab, lurbinectedin, and paclitaxel—used in the treatment of advanced solid tumors. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis. Lurbinectedin is a small molecule that binds to DNA minor grooves and inhibits transcription, leading to cancer cell death. Paclitaxel is a taxane chemotherapy that stabilizes microtubules, preventing cell division and inducing apoptosis in cancer cells. The combination has shown synergism in preclinical studies and manageable toxicity profiles in clinical trials[1][3][5].
- Brand names
- Zepzelca
- Other names
- paclitaxel/lurbinectedin/BEVpaclitaxel/lurbinectedin/bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + lurbinectedin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + lurbinectedin + paclitaxel.